Volume | 2,189,239 |
|
|||||
News | - | ||||||
Day High | 74.56 | Low High |
|||||
Day Low | 70.93 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Intra Cellular Therapies Inc | ITCI | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
72.31 | 70.93 | 74.56 | 72.37 | 72.00 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
29,209 | 2,189,239 | $ 72.68 | $ 159,104,834 | - | 45.50 - 84.89 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
16:29:19 | 30 | $ 72.37 | USD |
Intra Cellular Therapies (ITCI) Options Flow Summary
Intra Cellular Therapies Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
7B | 96.81M | - | 464.37M | -139.67M | -1.44 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Intra Cellular Therapies News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical ITCI Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 68.04 | 84.89 | 64.155 | 75.99 | 3,208,442 | 4.33 | 6.36% |
1 Month | 68.74 | 84.89 | 64.155 | 73.43 | 1,252,683 | 3.63 | 5.28% |
3 Months | 67.53 | 84.89 | 62.78 | 71.20 | 938,631 | 4.84 | 7.17% |
6 Months | 52.07 | 84.89 | 45.50 | 65.34 | 937,442 | 20.30 | 38.99% |
1 Year | 62.34 | 84.89 | 45.50 | 62.84 | 820,433 | 10.03 | 16.09% |
3 Years | 31.22 | 84.89 | 28.40 | 53.64 | 764,901 | 41.15 | 131.81% |
5 Years | 12.22 | 84.89 | 6.75 | 38.22 | 939,915 | 60.15 | 492.23% |
Intra Cellular Therapies Description
Intra-Cellular Therapies Inc is a biopharmaceutical company that develops novel drugs for treating diseases of the central nervous system. The company is focused on the delivery and clinical development of small-molecule drugs that address needs in neuropsychiatric and neurological disorders. Intra-Cellular maintains proprietary chemistry platforms to develop drugs for neurodegenerative diseases. The company's business segment is discovering and developing drugs for the treatment of neurological and psychiatric disorders. |